Can-Fite BioPharma Ltd. (TLV:CANF)
Israel
· Delayed Price · Currency is ILS · Price in ILA 1.500
0.00 (0.00%)
Apr 24, 2025, 5:24 PM IDT
Can-Fite BioPharma Revenue
In the year 2024, Can-Fite BioPharma had annual revenue of $674.00K USD, down -9.29%. Can-Fite BioPharma had revenue of $179.00K in the quarter ending December 31, 2024, with 15.48% growth.
Revenue
$674.00K
Revenue Growth
-9.29%
P/S Ratio
23.79
Revenue / Employee
$134.80K
Employees
5
Market Cap
58.40M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 60.26B |
| Danel (Adir Yeoshua) | 2.77B |
| Kamada | 586.24M |
| Bait Bakfar | 103.40M |
| Novolog (Pharm-Up 1966) | 2.02B |
| Ilex Medical | 920.37M |
| BrainsWay | 149.39M |
| SofWave Medical | 217.27M |
Can-Fite BioPharma News
- 10 days ago - Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients - GlobeNewsWire
- 12 days ago - Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 13 days ago - Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.67M - Seeking Alpha
- 5 weeks ago - Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market - GlobeNewsWire
- 5 weeks ago - Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson - GlobeNewsWire
- 7 weeks ago - Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits - GlobeNewsWire
- 2 months ago - Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25 - GlobeNewsWire
- 2 months ago - Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025 - GlobeNewsWire